@article{047df9365f1b4b00a041f84fcbef6b23,
title = "Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers",
abstract = "Nalmefene has been approved in Europe for the treatment of alcohol dependence and subsequently recommended by the UK National Institute for Health and Care Excellence (NICE). This study examines critically the evidence base underpinning both decisions and the issues arising. Published studies of nalmefene were identified through a systematic search, with documents from the European Medicines Agency, the NICE appraisal and public clinical trial registries also examined to identify methodological issues.",
keywords = "addiction, alcohol, brief intervention, nalmefene, trial regulation, vested interests",
author = "Niamh Fitzgerald and Kathryn Angus and Andrew Elders and {de Andrade}, Marisa and Duncan Raistrick and Jim McCambridge and Nick Heather",
note = "Paid open option for this journal (Wiley) Funders in Acknowledgements: The authors would like to acknowledge the helpful input on earlier drafts made by the anonymous peer reviewers and colleagues including, but not limited to: Srinivasa Vittal Katikireddi, James Nicholls, Colin Angus, James Morris and Peter Rice. N.F. and K.A. are employed by the Institute for Social Marketing, which is part of the UK Centre for Tobacco and Alcohol Studies (www.ukctas.ac.uk). Funding for UKCTAS from the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the Medical Research Council and the National Institute of Health Research, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. ",
year = "2016",
month = jul,
doi = "10.1111/add.13438",
language = "English",
volume = "111",
pages = "1477–1487",
journal = "Addiction",
issn = "0965-2140",
publisher = "Wiley",
number = "8",
}